Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome-Reference-Cited by-同舟云学术

Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome

Published:2011-01 Issue:1-2 Volume:412 Page:143-147
ISSN:0009-8981
Container-title:Clinica Chimica Acta
language:en
Short-container-title:Clinica Chimica Acta

Author:

Lucero Diego,Zago Valeria,López Graciela I.,Graffigna Mabel,Fainboim Hugo,Miksztowicz Verónica,Meroño Tomás,Belli Susana,Levalle Oscar,Wikinski Regina,Brites Fernando,Berg Gabriela,Schreier Laura

Publisher

Elsevier BV

Subject

Biochemistry, medical,Clinical Biochemistry,Biochemistry,General Medicine

Reference30 articles.

1. From the metabolic syndrome to NAFLD or vice versa?;Vanni;Dig Liver Dis,2010

2. The metabolic syndrome — an ongoing story;Duvnjak;J Physiol Pharmacol,2009

3. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?;Hui;Hepatology,2004

4. Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome;Gómez Rosso;Atherosclerosis,2008

5. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease;Sookoian;Atherosclerosis,2010

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokines and Inflammatory Markers in Nonalcoholic Fatty Liver Disease: A Narrative Review;Journal of the Scientific Society;2023-09

2. Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease;Frontiers in Pharmacology;2022-09-05

3. The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial;European Journal of Pharmacology;2021-09

4. On the Relationship Between Non-alcoholic Fatty Liver Disease with Body Composition and Bone Mineral Density in Overweight/Obese Adolescents;Hepatitis Monthly;2021-04-24

5. A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease;BMC Gastroenterology;2021-04-01